AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alpha-methylacyl-CoA racemase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9UHK6

UPID:

AMACR_HUMAN

Alternative names:

2-methylacyl-CoA racemase

Alternative UPACC:

Q9UHK6; A5YM47; B8Y916; B8Y918; F8W9N1; O43673; Q3KT79; Q96GH1; Q9Y3Q1

Background:

Alpha-methylacyl-CoA racemase, also known as 2-methylacyl-CoA racemase, plays a crucial role in the metabolism of fatty acids, facilitating the conversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters. This enzyme's activity is pivotal in processing a variety of substrates, including pristanoyl-CoA and trihydroxycoprostanoyl-CoA, essential in bile acid synthesis.

Therapeutic significance:

The enzyme's dysfunction is linked to Alpha-methylacyl-CoA racemase deficiency and Congenital bile acid synthesis defect 4, diseases characterized by neurodegenerative symptoms and cholestasis, respectively. Understanding the role of Alpha-methylacyl-CoA racemase could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.